Canaccord Genuity Group Cuts TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price reduced by Canaccord Genuity Group from $12.00 to $11.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also weighed in on the company. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Roth Mkm started coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Oppenheimer assumed coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and an average target price of $12.08.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSI opened at $3.93 on Friday. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The stock has a market capitalization of $119.83 million, a price-to-earnings ratio of -1.58 and a beta of 0.49. The business has a 50-day moving average of $4.33 and a 200-day moving average of $5.75.

Insider Activity at TriSalus Life Sciences

In other news, CEO Mary T. Szela acquired 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the acquisition, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. The trade was a 2.03 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 32.80% of the stock is owned by company insiders.

Institutional Trading of TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter worth $240,000. Highbridge Capital Management LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $1,184,000. Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the period. Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $66,000. Finally, MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $184,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.